NCT06680440View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

April 3, 2025

Study Completion Date

April 3, 2025

Conditions

Weight Management

Interventions

DRUG

ASC30

Tablet, QD

OTHER

Placebo

Tablets, QD

Trial Locations (1)

84124

Ascletis clinical site, Salt Lake City

All Listed Sponsors

lead

Ascletis Pharma (China) Co., Limited

INDUSTRY